ANONYMOUS CONTACTABLE MEMBER OF THE PUBLIC v JANSSEN
NO BREACH OF THE CODE
Clinical trial disclosure (Incivo)
An anonymous, contactable member of the public complained about the information published as ‘Clinical Trial Transparency: an assessment of the disclosure results of company-sponsored trials associated with new medicines approved recently in Europe’. The study was published in Current Medical Research & Opinion (CMRO) on 11 November 2013.
The study authors were Dr B Rawal, Research, Medical and Innovation Director at the ABPI and B R Deane, a freelance consultant in pharmaceutical marketing and communications. Publication support for the study was funded by the ABPI.
The study surveyed various publicly available information sources for clinical trial registration and disclosure of results searched from 27 December 2012 to 31 January 2013. It covered 53 new medicines (except vaccines and fixed dose combinations) approved for marketing by 34 companies by the European Medicines Agency (EMA) in 2009, 2010 and 2011. It included all completed company-sponsored clinical trials conducted in patients and recorded on a clinical trial registry and/or included in a European Public Assessment Report (EPAR). The CMRO publication did not include the specific data for each product. This was available via a website link and was referred to by the complainant. The study did not aim to assess the content of disclosure against any specific requirements.
The complainant stated that the study detailed a number of companies which had not disclosed their clinical trial results in line with the ABPI for licensed products. The complainant provided a link to relevant information which included the published study plus detailed information for each product that was assessed.
The summary output for each medicine set out the sources for all trials found, irrespective of sponsor and an analysis of publication disclosure in the form of a table which gave details for the studies for Incivo (telaprevir).
The detailed response from Janssen is given below.
General detailed comments from the Panel are given below.
The Panel noted the CMRO publication in that eight evaluable studies had not been disclosed within the timeframe. The disclosure percentage was 56%. The disclosure percentage at 31 January 2013 for trials completed by end of January 2012 was 78%. A footnote stated that the Tibotec BVBA trials had been disclosed and were publicly available but were not captured by the methodology. They had been submitted to clinicaltrials.gov. The remaining trials were not sponsored by Johnson & Johnson.
The Panel noted Janssen’s submission that only two of the eight trials had been sponsored by a Johnson & Johnson company (Tibotec BVBA). The first approval for Incivo/Incivek was granted in May 2011. The one study with UK involvement finished in May 2009 and was published in September 2011 which was within the timeframe given the product was first approved in May 2011. Thus the Panel ruled no breach of the 2011 Code including Clause 2.
An anonymous, contactable member of the public complained about the information published as ‘Clinical Trial Transparency: an assessment of the disclosure results of company-sponsored trials associated with new medicines approved recently in Europe’. The study was published in Current Medical Research & Opinion (CMRO) on 11 November 2013.
The study authors were Dr B Rawal, Research, Medical and Innovation Director at the ABPI and B R Deane, a freelance consultant in pharmaceutical marketing and communications. Publication support for the study was funded by the ABPI.
The study surveyed various publicly available information sources for clinical trial registration and disclosure of results searched from 27 December 2012 to 31 January 2013. It covered 53 new medicines (except vaccines and fixed dose combinations) approved for marketing by 34 companies by the European Medicines Agency (EMA) in 2009, 2010 and 2011. It included all completed company-sponsored clinical trials conducted in patients and recorded on a clinical trial registry and/or included in a European Public Assessment Report (EPAR). The CMRO publication did not include the specific data for each product. This was available via a website link and was referred to by the complainant. The study did not aim to assess the content of disclosure against any specific requirements.
COMPLAINT
The complainant stated that the study detailed a number of companies which had not disclosed their clinical trial results in line with the ABPI for licensed products. The complainant provided a link to relevant information which included the published study plus detailed information for each product that was assessed.
The summary output for each medicine set out the sources for all trials found, irrespective of sponsor and an analysis of publication disclosure in the form of a table which gave details for the studies for the products. The data for Incivo (telaprevir) were as follows:
The explanation of terms given in the documentation was as follows:
Total
Total number of trials identified which were completed and/or with results disclosed
Unevaluable
Trials within the total which could not be evaluated (due to either trial completion date or publication date being missing or unclear) – excluded from the analysis
Evaluable
Trials with all criteria present including dates, and hence the base which could be evaluated for the assessment
Results disclosed in timeframe
Evaluable trials which fully complied with publication requirements, ie summary results disclosed (in registry or journal) within 12 months of either first regulatory approval date or trial completion date, whichever was later
Disclosure percentage
Proportion of evaluable trials which were fully disclosed
Completed before end of January 2012
Number of studies completed before end January 2012 (or already disclosed)
Results disclosed at all
Number of trials with any publication of results at any time
Disclosure percentage at 31 January 2013
Proportion of trials completed by end January 2012 which were now disclosed
* * *
The complainant listed the companies he/she would like to complain about and this included Janssen.
The complainant alleged that all of the companies listed had breached Clauses 2, 9 and 21 of the Code.
When writing to Janssen, the Authority drew attention to Clauses 1.8 and 21.3 of the Second 2012 Edition of the Code and noted that previous versions of the Code might also be relevant.
RESPONSE
Janssen stated that the complainant appeared to have accused a large number of pharmaceutical companies and included in his/her list of companies and pharmaceutical products ‘J&J for Incivo’. A breach of Clauses 21, 9 and 2 of the Code was alleged. As Clauses 21.1 and 21.2 did not appear to be relevant to the complaint, Janssen assumed the complainant was only alleging a breach of Clause 21.3. The PMCPA also indicated that Janssen should consider Clause 1.8.
Janssen responded to the complaint in relation to the clinical trials for Incivo (telaprevir) that Johnson & Johnson companies had sponsored.
Janssen understood from one of the authors of the CMRO publication that two clinical trials sponsored by Tibotec BVBA (part of the Johnson & Johnson family of companies) contributed to the finding of ‘non-disclosed’ clinical trials in relation to Incivo (telaprevir) using the authors’ methodology. Janssen submitted that this methodology was not necessarily definitive with regard to disclosure in relation to clinical trials.
The studies in question were VX-950-TIDP24-C209 (‘C209’) and VX-950-TIDP24-C210 (‘C210’) which appeared as the first two of the 10 clinical trials identified. The list of clinical trials so identified and sent to Janssen on 27 February 2013 was provided. The other eight telaprevir clinical trials listed were sponsored either by Mitsubishi Tanabe Pharma or Vertex Pharmaceuticals.
A footnote to the summary table included in the CMRO publication stated, ‘Information from Johnson and Johnson: The results of the Tibotec BVBA trials have been disclosed and are publicly available, but were not captured by the methodology. They have been submitted to clinicaltrials.gov. The remaining trials were not sponsored by Johnson and Johnson’.
Janssen responded to the complaint only in relation to these two clinical trials as it could not take responsibility for disclosure of trials sponsored by other pharmaceutical companies.
Janssen provided the following information on the two Johnson & Johnson-sponsored studies:
C209
Clinicaltrials.gov Identifier: NCT00561015A
Title: A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants with Genotype 2 or 3 Hepatitis C Infection
The study included UK-based sites and the sponsor was based in Belgium.
First received in clinicaltrials.gov: 19 November 2007
Study start (first patient in): 6 December 2007
End of study: 28 May 2009
Results: Gastroenterology, September 2011; 141:881-889
C210
Clinicaltrials.gov Identifier: NCT00580801
Title: An Exploratory Study of Telaprevir in Treatment-Naïve Participants with Chronic Genotype 4 Hepatitis C Virus Infection
The study did not involve UK-based sites, subjects or investigators and was conducted in France. The sponsor was based in Belgium.
First received in clinicaltrials.gov: 20 December 2007
Study start (first patient in): 3 January 2008 End of study: 11 January 2010
Results: Manuscript initially submitted to Gastroenterology on 31 May 2012. Published eventually in Journal of Infectious Diseases 2013:208:1000-7.
Janssen submitted that the results of C210 were also presented:
- As an oral presentation at the European Association for the Study of the Liver (EASL) Meeting in 2009, abstract (Benhamou Y, et al.
Results of a Proof of Concept Study (C210) of Telaprevir Monotherapy and in Combination with Peginterferon Alfa-2a and Ribavirin in Treatment naive Genotype 4 HCV Patients. J Hepatol 2009;50(Suppl. 1):S6 (Abstract 10).
- As a poster at the American Association for Study of Liver Diseases (AALSD) Meeting in 2010 (Benhamou Y, et al. Activity of Telaprevir Monotherapy or in Combination with Peginterferon Alfa-2a and Ribavirin in Treatment naïve Genotype 4 Hepatitis C Patients: Final Results of Study C210. Hepatology 2010;52(Suppl. 1):719A (Abstract #828).
The first licence for Incivo/Incivek (telaprevir) globally was granted by the FDA in May 2011.
Thus, given the timings of the submission to a recognised clinical trial registry and dissemination of the results in relation to the date of first licence, Janssen submitted that both C209 and C210 were disclosed in accordance with Clause 21.3 and were compliant with the recommendations of the Joint Position 2009, and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature 2010. Janssen therefore maintained that it had complied with all applicable codes, laws and regulations and had not breached Clause 1.8.
Janssen submitted that Johnson & Johnson, and by default, Janssen had maintained high standards in relation to the disclosure and thus had not breached Clause 9. It had not brought the pharmaceutical industry into disrepute and thus Janssen also denied a breach of Clause 2.
Standard operating procedures (SOPs) and policy documents were provided these being: SOP-10376 Public Results Disclosure of Company-sponsored Clinical Trials, SOP-10377 Public Registration of Company-sponsored Clinical Trials and POL06204 Public registration and Results Disclosure of Company-sponsored Clinical Trials.
Since Janssen believed the complaint was without merit and it had provided evidence to support this view above, the company did not need to supply the additional information requested. This being details of all ongoing and completed trials in relation to telaprevir, such as dates of commencement, date of completion, the study type, and the nature and extent of any UK involvement etc.
in Janssen’s view the complaint was clearly based only on the clinical trials considered by the methodology of the CMRO publication, it was not appropriate to supply extensive information on various other clinical trials, for which there was no reason to believe that disclosure, compliant with the two Joint Positions, had not occurred.
Companies other than Johnson & Johnson had sponsored clinical trials with telaprevir and details were given. Neither Johnson & Johnson, nor Janssen-Cilag Ltd in the UK could take responsibility for the obligations of other sponsors in this regard and therefore no evidence in relation to clinical trials sponsored by these companies was offered.
In summary, Janssen submitted that the disclosure of the telaprevir trials sponsored by Johnson & Johnson, referred to in the CMRO publication complied with the joint positions and Clause 21.3.
Janssen stated that it took its obligations under the Code very seriously and it specifically refuted breaches of Clauses 1.8, 21, 9 and 2.
GENERAL COMMENTS FROM THE PANEL
The Panel noted the ABPI involvement in the study. However, a complaint had been received and it needed to be considered in the usual way in line with the PMCPA Constitution and Procedure. The Panel noted that all the cases would be considered under the Constitution and Procedure in the Second 2012 Edition as this was in operation when the complaint was received. The addendum (1 July 2013 which came into effect on 1 November 2013) to this Code only related to Clause 16 and was not relevant to the consideration of these cases.
The Panel noted that the study concluded that the results of over three quarters of all company sponsored clinical trials were disclosed within a year of completion or regulatory approval and almost 90% were disclosed by 31 January 2013 which suggested transparency was now better than had sometimes been reported previously.
The Panel considered that the first issue to be determined was whether the matter was covered by the ABPI Code. If the research was conducted on behalf of a UK pharmaceutical company (whether directly or via a third party) then it would be covered by the ABPI Code. If a study was run by a non UK company but had UK involvement such as centres, investigators, patients etc it was likely that the Code would apply. The Panel appreciated the global nature of much pharmaceutical company sponsored clinical research and a company located in the UK might not be involved in research that came within the ABPI Code. It was a well established principle that UK pharmaceutical companies were responsible for the activities of overseas affiliates if such activities related to UK health professionals or were carried out in the UK.
Clause 21.3 of the Second 2012 Edition of the Code stated that companies must disclose details of clinical trials in accordance with the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature.
The relevant supplementary information stated that this clause required the provision of details about ongoing clinical trials (which must be registered within 21 days of initiation of patients enrolment) and completed trials for medicines licensed for use in at least one country. Further information was to be found in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2009 and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature 2010, both at http://clinicaltrials.ifpma.org.
The Panel noted that the first Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases was agreed in 2005 by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Japanese Pharmaceutical Manufacturers Association (JPMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA). The announcement was dated 6 January 2005.
The Panel noted that Article 9, Clinical Research and Transparency, of the most recent update of the IFPMA Code of Practice (which came into operation on 1 September 2012) included a statement that companies disclose clinical trial information as set out in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases (2009) and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature (2010). As companies had, in effect, agreed the joint positions their inclusion in the IFPMA Code should not have made a difference in practice to IFPMA member companies but meant that IFPMA member associations had to amend their codes to reflect Article 9. The Second 2012 Edition of the ABPI Code fully reflected the requirements of the IFPMA Code. The changes introduced in the ABPI Code were to update the date of the Joint Position on the Disclosure of Clinical Trial Information and to include the new requirement to disclose in accordance with the Joint Position on the Publication of Clinical Trial Results. Pharmaceutical companies that were members of national associations but not of IFPMA would have additional disclosure obligations once the national association amended its code to meet IFPMA requirements. The disclosures set out in the joint positions were not required by the EFPIA Codes.
The Panel noted that even if the UK Code did not apply many of the companies listed by the complainant were members of IFPMA and/or EFPIA.
The Panel considered that it was good practice for clinical trial results to be disclosed for medicines which were first approved and commercially available after 6 January 2005 (the date of the first joint position). This was not necessarily a requirement of the ABPI Codes from that date as set out below.
As far as the ABPI Code was concerned, the Panel noted that the first relevant mention of the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2005 was in the supplementary information to Clause 7.5 of the 2006 Code:
‘Clause 7.5 Data from Clinical Trials
Companies must provide substantiation following a request for it, as set out in Clause 7.5. In addition, when data from clinical trials is used companies must ensure that where necessary that data has been registered in accordance with the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2005.’
Clause 7.5 of the 2006 Code required that substantiation be provided at the request of health professionals or appropriate administrative staff. Substantiation of the validity of indications approved in the marketing authorization was not required. The Panel considered this was not relevant to the complaint being considered which was about disclosure of clinical trial results. The Joint Position 2005 was mentioned in the supplementary information to Clause 21.5 but this did not relate to any Code requirement to disclose clinical trial results.
In the 2008 ABPI Code (which superceded the 2006 Code and came into operation on 1 July 2008 with a transition period until 31 October 2008 for newly introduced requirements), Clause 21 referred to scientific services and
Clause 21.3 stated:
‘Companies must disclose details of clinical trials.’
The relevant supplementary information stated:
‘Clause 21.3 Details of Clinical Trials
This clause requires the provision of details about ongoing clinical trials (which must be registered within 21 days of initiation of patients enrolment) and completed trials for medicines licensed for use in at least one country. Further information can be found in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2005 (http:// clinicaltrials.ifpma.org).
Details about clinical trials must be limited to factual and non-promotional information. Such information must not constitute promotion to health professionals, appropriate administrative staff or the public.’
In the 2011 Code (which superceded the 2008 Code and came into operation on 1 January 2011 with a transition period until 30 April 2011 for newly introduced requirements), the supplementary information to Clause 21.3 was updated to refer to the 2008 IFPMA Joint Position.
In the Second 2012 Edition (which came into operation on 1 July 2012 with a transition period until 31 October 2012 for newly introduced requirements), changes were made to update the references to the joint position and to include the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature.
Clause 21.3 now stated:
‘Companies must disclose details of clinical trials in accordance with the Joint Position on the Disclosure of Clinical Trial Information via Clinical
Trial Registries and Databases and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature.’
The relevant supplementary information stated:
‘Clause 21.3 Details of Clinical Trials
This clause requires the provision of details about ongoing clinical trials (which must be registered within 21 days of initiation of patients enrolment) and completed trials for medicines licensed for use in at least one country. Further information can be found in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2009 and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature 2010, both at http:// clinicaltrials.ifpma.org.
Details about clinical trials must be limited to factual and non-promotional information. Such information must not constitute promotion to health professionals, appropriate administrative staff or the public.’
The Panel noted that in the 2014 ABPI Code the disclosure requirements which had previously been stated in Clause 21 had been moved to Clause 13. In addition, the supplementary information stated that companies must include on their website information as to where details of their clinical trials could be found. The 2014 Code would come into effect on 1 May 2014 for newly introduced requirements following a transition period from 1 January 2014 until 30 April 2014.
The Panel examined the Joint Position on the Disclosure of Clinical Trial Information which was updated on 10 November 2009 and superseded the Joint Position 2008. With regard to clinical trial registries the document stated that all trials involving human subjects for Phase I and beyond at a minimum should be listed. The details should be posted no later than 21 days after the initiation of enrolment. The details should be posted on a free publicly accessible internet-based registry. Examples were given. Each trial should be given a unique identifier to assist in tracking. The Joint Position 2009 provided a list of information that should be provided and referred to the minimum Trial Registration Data Set published by the World Health Organisation (WHO). The Joint Position 2009 referred to possible competitive sensitivity in relation to certain data elements and that, in exceptional circumstances, this could delay disclosure at the latest until after the medicinal product was first approved in any country for the indication being studied. Examples were given.
The Panel noted that the complaint related to the disclosure of clinical trial results.
With regard to the disclosure of clinical trial results the Joint Position 2009 stated that the results for a medicine that had been approved for marketing and was commercially available in at least one country should be publicly disclosed. The results should be posted no later than one year after the medicine was first approved and commercially available. The results for trials completed after approval should be posted one year after trial completion – an adjustment to this schedule was possible to comply with national laws or regulations or to avoid compromising publication in a peer-reviewed medical journal.
The Joint Position 2009 included a section on implementation dates and the need for companies to establish a verification process.
The Joint Position 2005 stated that the results should be disclosed of all clinical trials other than exploratory trials conducted on a medicine that was approved for marketing and was commercially available in at least one country. The results generally should be posted within one year after the medicine was first approved and commercially available unless such posting would compromise publication in a peer-reviewed medical journal or contravene national laws or regulations. The Joint Position 2008 was dated 18 November 2008 and stated that it superseded the Joint Position 2005 (6 January and 5 September). The Joint Position 2008 stated that results should be posted no later than one year after the product was first approved and commercially available in any country. For trials completed after initial approval these results should be posted no later than one year after trial completion. These schedules would be subject to adjustment to comply with national laws or regulations or to avoid compromising publication in a peer reviewed medical journal.
The Joint Position on the Publication of Clinical Trial Results in the Scientific Literature was announced on 10 June 2010. It stated that all industry sponsored clinical trials should be considered for publication and at a minimum results from all Phase III clinical trials and any clinical trials results of significant medical importance should be submitted for publication. The results of completed trials should be submitted for publication wherever possible within 12 months and no later than 18 months of the completion of clinical trials for already marketed medicines and in the case of investigational medicines the regulatory approval of the new medicine or the decision to discontinue development.
Having examined the various codes and joint positions, the Panel noted that the Joint Position 2005 excluded any clinical trials completed before 6 January 2005. The position changed on 18 November 2008 as the Joint Position 2008 did not have any exclusion relating solely to the date the trial completed. The Joint Position 2009 was similar to the Joint Position 2008 in this regard.
The Panel noted that deciding which Code applied, and thus which joint position, was complicated. It noted that the 2011 Code which, taking account the transition period, came into operation on 1 May 2011 was the first edition of the Code to refer to the Joint Position 2008.
The Panel concluded that from 1 November 2008, (allowing for the transition period) until 30 April 2011 under the 2008 Code companies were required to follow the Joint Position 2005. From 1 May 2011 until 31 October 2012 under the 2012 Code companies were required to follow the Joint Position 2008. Since 1 November 2012 companies were required to follow the Joint Position 2009. The Panel considered that since the 2008 Code companies were, in effect, required to comply with the Joint Position cited in the relevant supplementary information. The relevant supplementary information gave details of what was meant by Clause 21.3 (Clause 13.1 in the 2014 Code). The Panel accepted that the position was clearer in the Second 2012 Edition of the Code. The Panel noted that the 2011 Code should have been updated to refer to the Joint Position 2009.
For medicines first licensed and commercially available in any country from 1 November 2008 until 30 April 2011 the results of clinical trials completed before 6 January 2005 would not have to be posted.
From 1 May 2011 there was no exclusion of trials based solely on completion date and so for a product first licensed and commercially available anywhere in the world after 1 May 2011 the applicable joint positions required relevant clinical trial results to be posted within a year of the product being first approved and commercially available or within a year of trial completion for trials completed after the medicine was first available.
Noting that the complaint concerned licensed products the Panel considered that the trigger for disclosure was the date the product was first approved and commercially available anywhere in the world. This would determine which version of the Code (and joint position) applied for trials completed prior to first approval. The next consideration was whether the trial completed before or after this date. For trials completing after the date of first approval, the completion date of the trial would determine which Code applied. The Panel considered that the joint positions encouraged disclosure as soon as possible and by no later than 1 year after first availability or trial completion as explained above. The Panel thus considered that its approach was a fair one. In this regard, it noted that the complaint was about whether or not trial results had been disclosed, all the joint positions referred to disclosure within a one year timeframe and companies needed time to prepare for disclosure of results. The Panel considered that the position concerning unlicensed indications or presentations of otherwise licensed medicines etc would have to be considered on a case by case basis bearing in mind the requirements of the relevant joint position and the legitimate need for companies to protect intellectual property rights. The Panel followed the decision tree set out below which it considered set out all the relevant possibilities.
During its development of the decision tree, the Panel sought advice from Paul Woods, BPharm MA (Medical Ethics and Law) of Paul Woods Compliance Ltd who provided an opinion. Mr Woods was not provided with details of the complaint or any of the responses. The advice sought was only in relation to the codes and joint positions.
The Panel considered the complaint could be read in two ways: firstly that the companies listed had not disclosed the data referred to in the CMRO publication relating to the products named or secondly, more broadly, that the companies had not disclosed the clinical trial data for the product named ie there could be studies in addition to those looked at in the CMRO publication. The Panel decided that it would consider these cases in relation to the studies covered by the CMRO publication and not on the broader interpretation. Companies would be well advised to ensure that all the clinical trial results were disclosed as required by the Codes and joint positions. The Panel considered that there was no complaint about whether the results disclosed met the requirements of the joint positions so this was not considered. In the Panel’s view the complaint was only about whether or not study results had been disclosed and the timeframe for such disclosure.
The CMRO publication stated that as far as the IFPMA Joint Position was concerned implementation had been somewhat variable in terms of completeness and timing. The Panel noted that a number of studies were referred to in the CMRO publication as ‘unevaluable’ and these were not specifically mentioned by the complainant. The CMRO publication focussed on the disclosure of evaluable trial results and the Panel only considered those evaluable trials.
The Panel noted that its consideration of these cases relied upon the information provided by the respondent companies. The CMRO publication did not identify the studies evaluated; it only provided quantitative data.
The Panel noted that the study ran from 27 December 2012 to 31 January 2013 and was published in November 2013. The Panel considered that companies that might not have been in line with various disclosure requirements had had a significant period of time after the study completed and prior to the current complaint being received to have disclosed any missing information. It appeared that the authors of the CMRO publication had contacted various companies for additional information.
Decision Tree - developed by the Panel when considering the complaint about the disclosure of clinical trial results. For expanded version of Decision Tree see Case Report PDF page 160
The Panel noted that the case preparation manager raised Clause 1.8 of the Second 2012 Edition with the companies. The supplementary information to Clause 1.8, Applicability of Codes, inter alia, referred to the situation when activities involved more than one country or where a pharmaceutical company based in one country was involved in activities in another country. The complainant had not cited Clause 1.8. The Panel noted that any company in breach of any applicable codes, laws or regulations would defacto also be in breach of Clause 1.8 of the Code; the converse was true. The Panel thus decided that as far as this complaint was concerned, any consideration of a breach or otherwise of Clause 1.8 was covered by other rulings and it decided, therefore, not to make any ruling regarding this clause (or its equivalent in earlier versions of the Code).
PANEL RULING IN CASE AUTH/2676/11/13
The Panel noted the CMRO publication in that eight evaluable studies had not been disclosed within the timeframe. The disclosure percentage was 56%. The disclosure percentage at 31 January 2013 for trials completed by end of January 2012 was 78%. A footnote stated that the Tibotec BVBA trials had been disclosed and were publicly available but were not captured by the methodology. They had been submitted to clinicaltrials.gov. The remaining trials were not sponsored by Johnson & Johnson.
The Panel noted Janssen’s submission that only two of the eight trials had been sponsored by a Johnson & Johnson company (Tibotec BVBA). The first approval for Incivo/Incivek was granted in May 2011. The two studies in question (C209 and C210) had been published. Study C209 finished in May 2009 and was published in September 2011 which was within the timeframe given the product was first approved in May 2011. Thus the Panel ruled no breach of Clause 21.3 of the 2011 Code and consequently no breach of Clauses 9.1 and 2.
With regard to Study C210, the Panel noted Janssen’s submission that it had been conducted outside the UK with no UK involvement (be that UK company or UK centres). The Panel considered as there was no UK involvement, the matter did not come within the scope of the UK Code and therefore ruled no breach.
Complaint received 21 November 2013
Case completed 20 March 2014
see cases:
3005,2908,2906,2903,2898,2763,2676,2674,2673,2672,2671,2670,2669,2667,2666,2665,2664,
2663,2662,2661,2659,2657,2654
